Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
Panobinostat: a novel mechanism of action shows promise in multiple myeloma

Following an initial “no” vote from the Oncologic Drugs Advisory Committee (ODAC) in late 2014, the US Food and Drug Administration eventually awarded accelerated approval in February 2015 to the histone deacetylase (HDAC) inhibitor panobinostat for use in select patients with relapsed multiple myeloma. Panobinostat has a novel mechanism of action that demonstrates synergy with the proteasome inhibitor bortezomib and the immunomodulatory agent dexamethasone, which translated into improved progression-free survival (PFS) for patients with multiple myeloma who had received at least 2 prior therapies, according to data from a prespecified subgroup analysis from the Panorama-1 trial.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(8)
Publications
Topics
Page Number
278-281
Legacy Keywords
panobinostat, multiple myeloma, bortezomib, dexamethasone, Panorama-1, histone deacetylases, HDACs
Sections
Article PDF
Article PDF

Following an initial “no” vote from the Oncologic Drugs Advisory Committee (ODAC) in late 2014, the US Food and Drug Administration eventually awarded accelerated approval in February 2015 to the histone deacetylase (HDAC) inhibitor panobinostat for use in select patients with relapsed multiple myeloma. Panobinostat has a novel mechanism of action that demonstrates synergy with the proteasome inhibitor bortezomib and the immunomodulatory agent dexamethasone, which translated into improved progression-free survival (PFS) for patients with multiple myeloma who had received at least 2 prior therapies, according to data from a prespecified subgroup analysis from the Panorama-1 trial.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Following an initial “no” vote from the Oncologic Drugs Advisory Committee (ODAC) in late 2014, the US Food and Drug Administration eventually awarded accelerated approval in February 2015 to the histone deacetylase (HDAC) inhibitor panobinostat for use in select patients with relapsed multiple myeloma. Panobinostat has a novel mechanism of action that demonstrates synergy with the proteasome inhibitor bortezomib and the immunomodulatory agent dexamethasone, which translated into improved progression-free survival (PFS) for patients with multiple myeloma who had received at least 2 prior therapies, according to data from a prespecified subgroup analysis from the Panorama-1 trial.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 13(8)
Issue
The Journal of Community and Supportive Oncology - 13(8)
Page Number
278-281
Page Number
278-281
Publications
Publications
Topics
Article Type
Display Headline
Panobinostat: a novel mechanism of action shows promise in multiple myeloma
Display Headline
Panobinostat: a novel mechanism of action shows promise in multiple myeloma
Legacy Keywords
panobinostat, multiple myeloma, bortezomib, dexamethasone, Panorama-1, histone deacetylases, HDACs
Legacy Keywords
panobinostat, multiple myeloma, bortezomib, dexamethasone, Panorama-1, histone deacetylases, HDACs
Sections
Citation Override
JCSO 2015;13(8):278-281
Disallow All Ads
Alternative CME
Article PDF Media